Autopsy report · NCT05629689
A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies
Cause of deathSlow enrollment
“GE-269-001 Part A in cancer patients was completed. Part B was significantly delayed due to slow recruitment and terminated early. This decision does not affect the Sponsor's continued commitment to advancing PET oncology diagnostics.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 3 years 6 months before it stopped.
- 19 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- GE Healthcare
- Sponsor type
- Industry
- Conditions
- Malignant Solid Tumor; Oncology
- Interventions
- GEH200520 Injection / GEH200521 (18F) Injection - Part A; Dynamic and Static - PET/CT scan; GEH200520 Injection / GEH200521 (18F) Injection - Part B; Static - PET/CT scan
- Participants
- 19
- Sites
- 2
- Countries
- Netherlands
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.